Arrowhead Pharmaceuticals Inc (FRA:HDP1)
€ 24.79 0.13 (0.53%) Market Cap: 3.07 Bil Enterprise Value: 2.91 Bil PE Ratio: 0 PB Ratio: 17.46 GF Score: 53/100

Arrowhead Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 10, 2020 / 03:20PM GMT
Release Date Price: €30.77 (-2.63%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good morning, everyone. Thanks for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're pleased to have Arrowhead Pharmaceuticals with us this morning. And from the company, we have Chris Anzalone, CEO; as well as Vince Anzalone, Vice President. With that, I'll turn it over to you, Chris.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

To start here, as you look to 2020, you're looking to move into extra hepatic tissues. And I think we saw your data sets last year and this year as well as you look at liver directed, but can you help us understand, as you go outside of liver-directed tissues, what are the key aspects of your technology and data to date that lend confidence to be able to achieve this?

Christopher R. Anzalone
Arrowhead Pharmaceuticals, Inc. - CEO, President & Director

Yes. Thanks very much, Salveen, and thanks very much for having us. It's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot